3 days Ago By ABMN Staff
Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS – Free Report ) – Investment analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L.
Watsek now forecasts that the company will post earnings per share of ($0.91) for the year, down from their prior forecast of ($0.50).
The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. CRVS has been the subject of several other research reports.
LADENBURG THALM/SH SH boosted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th.
StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Oppenheimer upped their price target on Corvus Pharmaceuticals from $8.
00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd.
One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.
83. Corvus Pharmaceuticals Trading Up 1.8 % Shares of Corvus Pharmaceuticals stock opened at $8.
34 on Monday. The stock has a market capitalization of $535.90 million, a price-to-earnings ratio of -9.
32 and a beta of 1.05. The firm’s 50-day moving average price is $6.
83 and its two-hundred day moving average price is $4.08. Corvus Pharmaceuticals has a 1-year low of $1.
30 and a 1-year high of $10.00. Institutional Trading of Corvus Pharmaceuticals A number of institutional investors have recently modified their holdings of CRVS.
Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $44,000. Nwam LLC bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $53,000. XTX Topco Ltd acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth $74,000.
Oppenheimer & Co. Inc. bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth $89,000.
Finally, Marshall Wace LLP acquired a new stake in Corvus Pharmaceuticals in the second quarter valued at about $136,000. 46.64% of the stock is currently owned by institutional investors.
About Corvus Pharmaceuticals ( Get Free Report ) Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. Further Reading Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
